Drug Profile


Alternative Names: Anti-CCR2 monoclonal antibody; MLN-1202; TAK-202

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium; Millennium Pharmaceuticals; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis; Diabetic nephropathies
  • Phase I Malignant melanoma
  • Discontinued Multiple sclerosis; Rheumatoid arthritis; Scleroderma

Most Recent Events

  • 01 Oct 2016 Takeda withdraws a phase I trial in Healthy volunteers prior to enrollment in Japan due to a business decision and no safety or efficacy concerns (NCT02426021)
  • 26 Jul 2016 Takeda terminates phase I trial in Healthy volunteers in Japan (NCT02426021)
  • 01 May 2016 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA (IV) (NCT02723006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top